In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Kevin Freeman Biography and Net Worth

Director of Galectin Therapeutics

Mr. Freeman holds the Chartered Financial Analyst designation and is Chief Executive Officer of Cross Consulting and Services, LLC, an investment advisory and consulting firm founded in 2004. He is also author of a New York Times bestselling book about the stock market and economy. Formerly he was Chairman of Separate Account Solutions, Inc. and held several offices at Franklin Templeton Investment Services from 1991 to 2000. He holds a B.S. in business administration from University of Tulsa, Tulsa, Oklahoma.

What is Kevin D. Freeman's net worth?: The estimated net worth of Kevin D. Freeman is at least $94,215.24 as of October 16th, 2024. Mr. Freeman owns 33,469 shares of Galectin Therapeutics stock worth more than $94,215 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Freeman may own. Learn More about Kevin D. Freeman's net worth.
How do I contact Kevin D. Freeman?: The corporate mailing address for Mr. Freeman and other Galectin Therapeutics executives is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. Galectin Therapeutics can also be reached via phone at (678) 620-3186 and via email at [email protected]. Learn More on Kevin D. Freeman's contact information.
Has Kevin D. Freeman been buying or selling shares of Galectin Therapeutics?: Within the last three months, Kevin D. Freeman has bought $13,500.00 of Galectin Therapeutics stock. Most recently, on Wednesday, October 16th, Kevin D. Freeman bought 5,000 shares of Galectin Therapeutics stock. The stock was acquired at an average cost of $2.70 per share, with a total value of $13,500.00. Following the completion of the transaction, the director now directly owns 33,469 shares of the company's stock, valued at $90,366.30. Learn More on Kevin D. Freeman's trading history.
Who are Galectin Therapeutics' active insiders?: Galectin Therapeutics' insider roster includes Kevin Freeman (Director), Elissa Schwartz (Director), and Richard Zordani, Jr. (Director). Learn More on Galectin Therapeutics' active insiders.
Are insiders buying or selling shares of Galectin Therapeutics?: During the last twelve months, Galectin Therapeutics insiders bought shares 7 times. They purchased a total of 12,259 shares worth more than $34,100.70. During the last twelve months, insiders at the sold shares 1 times. They sold a total of 21,323 shares worth more than $65,248.38. The most recent insider tranaction occured on October, 23rd when Director Kary Eldred bought 500 shares worth more than $1,300.00. Insiders at Galectin Therapeutics own 52.7% of the company. Learn More about insider trades at Galectin Therapeutics.
Information on this page was last updated on 10/23/2024.

Kevin D. Freeman Insider Trading History at Galectin Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/16/2024	Buy	5,000	$2.70	$13,500.00	33,469
4/22/2024	Buy	2,500	$2.98	$7,450.00	25,969
10/28/2022	Buy	10,000	$1.41	$14,100.00	75,000
5/19/2022	Buy	5,000	$1.33	$6,650.00	65,000
4/18/2022	Buy	5,000	$1.71	$8,550.00	60,000
1/19/2022	Buy	5,000	$1.96	$9,800.00
12/6/2021	Buy	5,000	$2.34	$11,700.00
10/29/2021	Buy	2,000	$3.17	$6,340.00
10/21/2021	Buy	2,000	$3.19	$6,380.00
10/19/2021	Buy	3,000	$3.37	$10,110.00
9/23/2021	Buy	3,000	$3.88	$11,640.00
4/5/2021	Buy	5,000	$2.04	$10,200.00	23,469
9/4/2020	Buy	5,000	$2.57	$12,850.00	23,469
3/19/2020	Buy	6,000	$1.69	$10,140.00
11/15/2019	Buy	3,000	$3.36	$10,080.00	23,469
9/6/2019	Buy	1,290	$3.71	$4,785.90	23,469
4/5/2019	Buy	500	$4.73	$2,365.00	22,043
2/8/2019	Buy	1,500	$4.29	$6,435.00	22,043
2/1/2018	Buy	2,000	$4.10	$8,200.00	22,043
6/1/2015	Buy	2,083	$2.70	$5,624.10
8/15/2014	Buy	1,000	$4.70	$4,700.00
5/28/2013	Buy	1,000	$4.21	$4,210.00

Kevin D. Freeman Buying and Selling Activity at Galectin Therapeutics

Galectin Therapeutics Company Overview

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Today's Range

Now: $2.77

$2.76

$2.90

50 Day Range

MA: $2.69

$2.47

$3.00

2 Week Range

Now: $2.77

$1.55

$4.27

Volume

76,858 shs

Average Volume

145,398 shs

Market Capitalization

$173.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad